GO:0048024 regulation of mRNA splicing, via spliceosome: Spliceosome Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048024 describes any process that modulates the frequency, rate or extent of mRNA splicing via a spliceosomal mechanism, encompassing the regulation of both constitutive and alternative pre-mRNA splicing.
• The spliceosome is a dynamic ribonucleoprotein machine whose assembly, activation and catalysis are controlled by reversible phosphorylation, ATP-dependent RNA helicases and auxiliary splicing factors.
• Key regulators include SF3B1, SF3B3, CDK7, CDK11, USP42 and the RES complex component SNIP1, which together coordinate spliceosome activation and exon recognition.
• Dysregulation of GO:0048024 is directly implicated in colorectal cancer progression, mantle cell lymphoma aggressiveness and EVI1-rearranged leukemia.
• CRISPR-based knockout, point-mutation, knock-in and overexpression models enable causal dissection of splicing regulators in disease-relevant cell backgrounds.
• Combining RNA-seq, Ribo-seq and interactome proteomics provides a systems-level readout of how a given regulator reshapes the splicing landscape.
Description
Regulation of mRNA splicing, via spliceosome (GO:0048024) is the biological process that controls the frequency, rate or extent of spliceosome-mediated removal of introns from precursor messenger RNA. Because more than 90 percent of human multi-exon genes undergo alternative splicing, the regulatory layer captured by GO:0048024 determines which protein isoforms a cell produces and therefore shapes nearly every aspect of cell physiology. The spliceosome itself is not a static enzyme but a highly dynamic assembly of small nuclear ribonucleoproteins and associated proteins that must be assembled, activated and proofread at each intron. Regulation of this process occurs at multiple levels. Splice site selection is influenced by cis-acting enhancers and silencers, by the concentration and post-translational modification of core splicing factors, and by ATP-dependent RNA helicases that remodel RNA-protein interactions during catalysis. Recent work has shown that kinase cascades, including the CDK7-CDK11 axis, and phosphorylation of SF3B1 by CDK11 control spliceosome activation through recruitment of the RES complex. Other regulators, such as the deubiquitinase USP42, act through phase separation to organize nuclear speckles and promote efficient splicing. For researchers, GO:0048024 matters because perturbation of this regulatory layer is a recurrent theme in cancer and other diseases. SF3B3-regulated alternative splicing of mTOR drives colorectal cancer progression and metastasis, splicing factors contribute to mantle cell lymphoma aggressiveness, and aberrant EVI1 splicing underlies EVI1-rearranged leukemia. Understanding which factors regulate splicing, and how, therefore provides both mechanistic insight and candidate therapeutic targets.
regulation of mRNA splicing, via spliceosome At A Glance
| GO ID | GO:0048024 |
|---|---|
| GO term | regulation of mRNA splicing, via spliceosome |
| Ontology | biological_process |
| Definition | Any process that modulates the frequency, rate or extent of mRNA splicing via a spliceosomal mechanism. |
| Synonym | regulation of nuclear mRNA splicing, via spliceosome; regulation of nuclear mRNA splicing via U2-type spliceosome; regulation of pre-mRNA splicing |
| Major function | Tuning spliceosome assembly, activation and splice site selection to control mRNA isoform output. |
| Process context | Pre-mRNA processing in the nucleus, coupled to transcription and RNA export. |
| Key regulators | SF3B1, SF3B3, CDK7, CDK11, USP42, SNIP1 and other spliceosomal and auxiliary factors. |
| Disease relevance | Cancer progression, leukemia, lymphoma and other splicing-associated disorders. |
What Is GO:0048024?
In plain terms, GO:0048024 covers all the processes that adjust how often, how fast or to what extent the spliceosome carries out mRNA splicing. It is not the catalysis of splicing itself but the regulatory inputs that tune spliceosome activity, splice site choice and the efficiency of intron removal. The QuickGO definition states that it is any process that modulates the frequency, rate or extent of mRNA splicing via a spliceosomal mechanism, and its synonyms include regulation of nuclear mRNA splicing, via spliceosome, regulation of nuclear mRNA splicing via U2-type spliceosome, and regulation of pre-mRNA splicing.
Why Is regulation of mRNA splicing, via spliceosome Important in Cell Biology?
GO:0048024 is important because the regulatory layer it describes determines the protein isoform repertoire of a cell, and its disruption is a direct driver of human disease. The spliceosome must be assembled and activated anew at each intron, and this process is controlled by phosphorylation, deubiquitination and phase separation events that are themselves frequently altered in cancer. For example, SF3B3-regulated alternative splicing of mTOR promotes colorectal cancer progression and metastasis, showing that a single regulatory node can reshape a oncogenic pathway. Similarly, splicing factors identified in mantle cell lymphoma influence disease aggressiveness, and aberrant EVI1 splicing contributes to EVI1-rearranged leukemia. Because these regulatory events are enzymatically tractable, they represent attractive targets for experimental perturbation and therapeutic intervention.
• Controls alternative splicing outcomes that expand proteome diversity from a limited genome.
• Determines splice site selection and exon inclusion during spliceosome assembly and activation.
• Integrates signaling kinase cascades such as CDK7-CDK11 into pre-mRNA processing.
• Links post-translational modification of splicing factors, including SF3B1 phosphorylation, to spliceosome activation.
• Connects nuclear organization and phase separation to splicing efficiency through factors such as USP42.
• Is dysregulated in colorectal cancer, where SF3B3-dependent mTOR splicing drives metastasis.
• Contributes to hematological malignancies including mantle cell lymphoma and EVI1-rearranged leukemia.
• Provides a rich source of candidate targets for CRISPR-based functional genomics.
• Enables mechanistic studies of how splicing regulators shape transcriptome-wide isoform usage.
What Happens During regulation of mRNA splicing, via spliceosome?
Spliceosome assembly and early recognition of splice sites
In simple terms: The cell first marks which parts of the RNA should be kept and which should be removed.
Regulation begins with recognition of the 5-prime splice site, branch point and polypyrimidine tract by U1 and U2 small nuclear ribonucleoproteins and associated factors. The U2 auxiliary factor and SF3B complex help define the branch point, and the composition of these early complexes determines whether an intron will be spliced efficiently. In Saccharomyces cerevisiae, this early recognition step is tightly coupled to ATP-dependent rearrangements that commit the pre-mRNA to splicing. Regulatory inputs at this stage include the availability and modification state of core splicing factors, which can shift splice site choice before catalysis begins.
Activation of the spliceosome and RES complex recruitment
In simple terms: A chemical switch flips the spliceosome from a poised state into a catalytically active machine.
Activation requires extensive remodeling of the spliceosome, including dissociation of U1 and U4 and stable integration of the U5 and U6 small nuclear ribonucleoproteins. Recent work shows that phosphorylation of SF3B1 by CDK11 orchestrates spliceosome activation through SNIP1-dependent recruitment of the RES complex. The CDK7-CDK11 kinase axis further regulates spliceosome function and pre-mRNA splicing, linking transcriptional kinases to splicing control. These phosphorylation events act as a regulatory checkpoint that ensures activation occurs only when appropriate.
Catalysis and proofreading of exon ligation
In simple terms: The spliceosome cuts the RNA and joins the exons, while checking that the join is correct.
During catalysis, two sequential transesterification reactions remove the intron and ligate the flanking exons. ATP-dependent RNA helicases remodel RNA-protein interactions to reposition the substrate and proofread the reaction. Regulatory factors can influence the fidelity and rate of these steps, thereby modulating the frequency and extent of splicing captured by GO:0048024. The dynamic nature of the spliceosome means that regulatory inputs can act even after the initial assembly steps.
Post-catalytic release and recycling of spliceosomal components
In simple terms: After splicing, the machine comes apart and its parts are reused for the next intron.
Following exon ligation, the spliceosome is disassembled and its components are recycled for subsequent rounds of splicing. This step is regulated by ATP-dependent helicases and by post-translational modifications that influence the stability and localization of splicing factors. Regulation at this stage affects the overall throughput of the splicing pathway and helps maintain splicing homeostasis. Disruption of recycling can alter the balance of spliced isoforms and contribute to disease.
Coupling of splicing regulation to nuclear organization
In simple terms: Splicing happens in specific compartments of the nucleus, and their organization affects how well it works.
Splicing factors concentrate in nuclear speckles, and the dynamic organization of these compartments influences splicing efficiency. USP42 drives nuclear speckle mRNA splicing via directing dynamic phase separation to promote tumorigenesis, illustrating how regulated condensation of splicing factors can control splicing output. This coupling means that regulators of GO:0048024 can act by changing where and when splicing factors assemble, not only by changing their catalytic activity. Such spatial regulation adds an additional layer of control over splice site selection and isoform production.
Key Genes Involved in GO:0048024 regulation of mRNA splicing, via spliceosome
The following genes and proteins are established regulators or core components whose activities are directly relevant to GO:0048024.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SF3B1 | Core spliceosome component; phosphorylation by CDK11 controls activation | Frequently mutated in cancer; target for activation studies |
| SF3B3 | Component of the SF3B complex; regulates alternative splicing of mTOR | Drives colorectal cancer progression and metastasis |
| CDK7 | Kinase that regulates spliceosome function and pre-mRNA splicing | Links transcription and splicing control |
| CDK11 | Kinase that phosphorylates SF3B1 and coordinates spliceosome activation | Central node in the CDK7-CDK11 axis |
| USP42 | Deubiquitinase that directs phase separation and nuclear speckle splicing | Promotes tumorigenesis via splicing regulation |
| SNIP1 | Mediates RES complex recruitment during spliceosome activation | Required for SF3B1-dependent activation |
| EVI1 | Transcription factor whose aberrant splicing contributes to leukemia | Model for splicing-driven leukemia |
| U2AF1 | Recognizes the polypyrimidine tract during early splice site selection | Core regulator of splice site choice |
| U2AF2 | Auxiliary factor that assists U2 snRNP recruitment | Modulates early spliceosome assembly |
| SRSF1 | Serine-arginine rich splicing factor that influences exon inclusion | Model for splicing factor overexpression studies |
| SRSF2 | Splicing factor involved in exon recognition and regulation | Relevant to splicing-associated malignancies |
| HNRNPA1 | Heterogeneous nuclear ribonucleoprotein that modulates splice site selection | Antagonizes SR protein function |
| PRPF8 | Core component of the U5 snRNP and catalytic core | Essential for spliceosome catalysis |
| SNRNP200 | RNA helicase that remodels the spliceosome during activation | ATP-dependent regulator of splicing |
| DDX5 | RNA helicase implicated in spliceosome remodeling | Regulator of splicing efficiency |
| DHX9 | RNA helicase that participates in splicing regulation | Modulates RNA-protein rearrangements |
| RBM39 | Splicing factor that influences exon recognition | Candidate regulator in cancer splicing networks |
| SRSF6 | SR protein family member that promotes exon inclusion | Relevant to splicing factor profiling in lymphoma |
How Is regulation of mRNA splicing, via spliceosome Regulated?
Regulation of GO:0048024 is itself controlled by signaling pathways and post-translational modifications. The CDK7-CDK11 kinase axis directly regulates spliceosome function and pre-mRNA splicing, providing a phosphorylation-dependent control layer. Phosphorylation of SF3B1 by CDK11 orchestrates spliceosome activation via SNIP1-dependent RES complex recruitment, showing how a single modification can gate a major activation step. Deubiquitination by USP42 regulates splicing through dynamic phase separation and nuclear speckle organization, linking ubiquitin signaling to splicing control. In addition, the availability and modification state of core splicing factors such as SF3B3 can reshape alternative splicing programs, as seen for mTOR in colorectal cancer. Together these mechanisms allow cells to tune splicing in response to growth, stress and oncogenic signals.
regulation of mRNA splicing, via spliceosome and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SF3B3 | Colorectal cancer progression and metastasis | Knockout or knockdown in colorectal cancer cell lines followed by RNA-seq |
| EVI1 | EVI1-rearranged leukemia | Point-mutation or knock-in models of splice isoforms in leukemia cells |
| SF3B1 | Spliceosome activation and cancer-associated splicing | Point mutation of phosphorylation sites to test CDK11-dependent activation |
| USP42 | Tumorigenesis via nuclear speckle splicing | Overexpression and knockout models to assess phase separation and splicing |
| CDK11 | Spliceosome regulation and pre-mRNA splicing | Knockout or inhibitor-treated models to test activation defects |
Colorectal cancer progression and metastasis
SF3B3-regulated alternative splicing of mTOR promotes colorectal cancer progression and metastasis, demonstrating that a specific splicing regulator within GO:0048024 can drive oncogenic phenotypes. This finding links spliceosome-associated regulation directly to a central growth pathway and suggests that targeting splicing regulators may alter mTOR isoform balance in tumors.
Mantle cell lymphoma aggressiveness
Identification and functional characterization of splicing factors implicated in mantle cell lymphoma aggressiveness has revealed that specific splicing regulators contribute to disease behavior. These factors operate within the regulatory layer described by GO:0048024 and represent candidate biomarkers or therapeutic targets in lymphoma.
EVI1-rearranged leukemia
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia, showing that misregulation of splicing can produce pathogenic isoforms of a key transcription factor. This provides a direct example of how altered regulation of mRNA splicing, via spliceosome, can contribute to hematological malignancy.
Spliceosome activation defects and therapeutic targeting
Because spliceosome activation is controlled by kinases such as CDK11 and by factors like SNIP1, perturbations in this regulatory step can have broad consequences for gene expression. Understanding these mechanisms supports the development of experimental models to test whether modulating GO:0048024-related factors can reverse disease-associated splicing patterns.
From regulation of mRNA splicing, via spliceosome-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a splicing regulator required for cell viability? | CRISPR knockout of the candidate gene in a disease-relevant cell line |
| Does a specific phosphorylation site control spliceosome activation? | Point mutation of the phospho-acceptor residue in SF3B1 or CDK11 substrates |
| Does a disease-associated isoform drive phenotype? | Knock-in of the isoform-specific sequence or minigene reporter |
| Where does a splicing factor localize and assemble? | Tagged knock-in with fluorescent or affinity tags for imaging and proteomics |
| Does overexpression of a splicing factor alter isoform usage? | Doxycycline-inducible overexpression followed by RNA-seq |
| Which splicing regulators cooperate in a cancer context? | CRISPR library screening combined with splicing-sensitive reporters |
How to Study the regulation of mRNA splicing, via spliceosome Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Exon inclusion, intron retention and isoform ratios | Transcriptome-wide splicing changes after regulator perturbation |
| Ribo-seq | Translating ribosome occupancy | Linking splicing changes to protein output |
| Affinity proteomics | Protein-protein interactions of spliceosomal complexes | Mapping regulators such as SF3B1 and SNIP1 |
| Phosphoproteomics | Site-specific phosphorylation changes | Identifying CDK11-dependent phosphorylation events |
| Fluorescence microscopy | Localization and condensation of splicing factors | Nuclear speckle and phase separation studies |
| Minigene reporters | Splicing of a defined exon-intron construct | Testing specific splice site or isoform effects |
| CRISPR knockout | Loss-of-function phenotype | Determining requirement for a candidate regulator |
| CRISPR library screening | Pooled fitness or reporter-based selection | Discovering splicing regulators in disease models |
Transcriptome-wide splicing analysis by RNA-seq
RNA-seq remains the primary method to quantify how perturbations in GO:0048024-related factors change exon inclusion, intron retention and isoform ratios. Studies of SF3B3-regulated mTOR alternative splicing used transcriptome analysis to link a splicing regulator to a specific oncogenic isoform. Similar approaches can be applied to any candidate regulator to define its splicing target network.
Proteomics and interactome mapping of spliceosomal complexes
Affinity purification coupled to mass spectrometry allows identification of proteins that associate with core spliceosome components and regulatory factors. This approach has been used to define how SF3B1 phosphorylation and SNIP1-dependent RES complex recruitment control activation. Interactome mapping helps place a candidate regulator within the assembly pathway of GO:0048024.
Imaging of nuclear speckles and phase-separated compartments
Fluorescence imaging of splicing factors and nuclear speckle markers reveals how regulators influence the spatial organization of the splicing machinery. USP42 was shown to drive nuclear speckle mRNA splicing via dynamic phase separation, illustrating the value of imaging-based readouts. Live-cell imaging can complement biochemical assays to test whether a regulator alters condensation dynamics.
Functional perturbation with CRISPR and pharmacological inhibitors
CRISPR knockout, point mutation and overexpression models, combined with kinase inhibitors, allow causal testing of regulatory hypotheses. The CDK7-CDK11 axis has been probed with such approaches to define its role in spliceosome regulation. These methods are essential for distinguishing correlation from causation in GO:0048024 research.
How CRISPR Can Be Used to Study GO:0048024 regulation of mRNA splicing, via spliceosome
Knockout
CRISPR knockout of candidate regulators is used to test whether a gene is required for normal splicing and cell fitness. For example, knocking out splicing factors implicated in mantle cell lymphoma can reveal effects on aggressiveness-associated phenotypes. Knockout of SF3B3 or related factors can be combined with RNA-seq to define the dependent splicing program.
Point Mutation
Point mutation is used to dissect specific regulatory residues, such as phosphorylation sites that control spliceosome activation. Mutation of the CDK11 target site in SF3B1 can test whether phosphorylation is required for SNIP1-dependent RES complex recruitment. This approach provides precise mechanistic information that knockout cannot deliver.
Knock-in
Knock-in models allow expression of specific splice isoforms or tagged proteins at endogenous loci. For EVI1-rearranged leukemia, knock-in of disease-associated isoforms can test their contribution to leukemic phenotypes. Tagged knock-in of splicing factors also supports imaging and interactome studies.
Overexpression
Overexpression of splicing factors or their regulatory partners can mimic oncogenic states and reveal dominant effects on isoform usage. Inducible overexpression of SR proteins or other regulators can shift exon inclusion patterns and provide a gain-of-function counterpart to knockout. This is particularly useful when the disease context involves increased splicing factor dosage.
How EDITGENE Supports regulation of mRNA splicing, via spliceosome Research
Researchers studying regulation of mRNA splicing, via spliceosome-related genes often need to determine whether a candidate gene is causally involved in a specific splicing or disease phenotype, and this requires precise, reproducible genome engineering. EDITGENE provides the full spectrum of CRISPR models and screening services needed to move from correlation to causation in splicing biology.
Contact EDITGENE today to design your custom CRISPR model for regulation of mRNA splicing, via spliceosome research.
Frequently Asked Questions About regulation of mRNA splicing, via spliceosome
What is GO:0048024 regulation of mRNA splicing, via spliceosome?
GO:0048024 is a Gene Ontology biological process term defined as any process that modulates the frequency, rate or extent of mRNA splicing via a spliceosomal mechanism.
What genes are involved in regulation of mRNA splicing, via spliceosome?
Key genes include SF3B1, SF3B3, CDK7, CDK11, USP42, SNIP1, EVI1 and core spliceosomal components such as PRPF8 and U2AF1.
Why is regulation of mRNA splicing important?
It determines which protein isoforms a cell produces and is frequently dysregulated in cancer and other diseases.
How is the spliceosome activated?
Activation involves remodeling of small nuclear ribonucleoproteins and phosphorylation events, including CDK11-dependent phosphorylation of SF3B1 and SNIP1-dependent RES complex recruitment.
What diseases are linked to splicing dysregulation?
Colorectal cancer, mantle cell lymphoma and EVI1-rearranged leukemia are examples where splicing regulators contribute to disease.
How can I study regulation of mRNA splicing in the lab?
Common approaches include RNA-seq, Ribo-seq, affinity proteomics, imaging of nuclear speckles and CRISPR-based perturbation.
What is the role of USP42 in splicing?
USP42 drives nuclear speckle mRNA splicing via dynamic phase separation and promotes tumorigenesis.
How does CDK11 regulate splicing?
CDK11 phosphorylates SF3B1 and orchestrates spliceosome activation through SNIP1-dependent RES complex recruitment.
Can CRISPR be used to study splicing regulators?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models are widely used to dissect splicing regulator function.
What services does EDITGENE offer for splicing research?
EDITGENE offers knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening with bioinformatics support for splicing studies.
Conclusion
GO:0048024 regulation of mRNA splicing, via spliceosome captures the essential regulatory layer that tunes spliceosome assembly, activation and catalysis to shape the cellular isoform landscape. Core factors such as SF3B1, SF3B3, CDK7, CDK11, USP42 and SNIP1 illustrate how phosphorylation, deubiquitination and phase separation converge on splicing control. Because dysregulation of this process contributes to colorectal cancer, mantle cell lymphoma and EVI1-rearranged leukemia, it is a high-value area for mechanistic and translational research. CRISPR-based models and multi-omics methods now make it feasible to move from correlation to causation for any candidate regulator within this process. By combining knockout, point-mutation, knock-in and overexpression strategies with RNA-seq, proteomics and imaging, researchers can define how specific factors control splicing and whether they represent viable therapeutic targets.
References
- 1. Senn KA et al.. 2024. Mechanisms and regulation of spliceosome-mediated pre-mRNA splicing in Saccharomyces cerevisiae.. Wiley Interdiscip Rev RNA 15(4):e1866 PMID: 38972853
- 2. Matera AG et al.. 2014. A day in the life of the spliceosome.. Nat Rev Mol Cell Biol 15(2):108-21 PMID: 24452469
- 3. Xu T et al.. 2024. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis.. J Exp Clin Cancer Res 43(1):126 PMID: 38671459
- 4. Rájecký M et al.. 2025. CDK7-CDK11 axis in spliceosome regulation and pre-mRNA splicing.. Nucleic Acids Res 53(22) PMID: 41428738
- 5. Liu S et al.. 2021. USP42 drives nuclear speckle mRNA splicing via directing dynamic phase separation to promote tumorigenesis.. Cell Death Differ 28(8):2482-2498 PMID: 33731873
- 6. Yosudjai J et al.. 2025. Identification and functional characterization of splicing factors implicated in mantle cell lymphoma aggressiveness.. Sci Rep 15(1):43709 PMID: 41388034
- 7. Gajdušková P et al.. 2026. Phosphorylation of SF3B1 by CDK11 orchestrates spliceosome activation via SNIP1-dependent RES complex recruitment.. Nat Commun 17(1) PMID: 41904131
- 8. Tanaka A et al.. 2022. Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.. Blood 140(8):875-888 PMID: 35709354
